Titulaire de licence: Medigen Vaccine Biologics Corp

Date: août 2023

En aoĂ»t 2023, dans le cadre du Groupement d’accĂšs aux technologies contre la COVID-19 (C-TAP) de l’OMS, le Medicines Patent Pool a signĂ© une licence de portĂ©e mondiale avec Medigen Vaccine Biologics Corp pour son vaccin MVC-COV1901 contre la COVID-19, qui avait obtenu une autorisation d’utilisation d’urgence (Emergency Use Authorization) Ă  Taipei en juillet 2021. À la date de la signature, plus de trois millions de doses de ce vaccin avaient dĂ©jĂ  Ă©tĂ© distribuĂ©es et administrĂ©es dans sept pays dans le cadre de cette autorisation.

MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for this technology by submitting an e-mail to C-TAPvaccines@medicinespatentpool.org  providing as much detail as possible as to what the developer intends to do with a sublicence.

Principales caractéristiques
Aim of the Licence To facilitate the manufacture and commercialisation of Covid-19 vaccine around the world.
 Products Any product that is covered by the patent rights, material, and know-how from Medigen.
Know‐how Medigen to provide all necessary know-how and materials to the licensees, specified in the license.
Field of use COVID-19 vaccine.
Territory Worldwide.
Scope of the grant Non-exclusive right to grant sublicences to develop the patent rights, material, and know-how into Products, and to commercialise Products.
Royalties Royalty rates apply on the net sales of the Products where there is a patent right granted and in force in the country of manufacture or sale as follows:

  • a royalty of 0.5% for low-income economies;
  • a royalty of 1% for lower-middle income economies;
  • a royalty of 3% for upper middle-income economies; and
  • a royalty of 5% for high-income economies.
Fees Technology fees apply to sublicensees, which includes one-time fees for entering into the sublicence; the licensed technology; basic support and training; the preparation of materials; the first launch of the Product; and also a running technology fee.
Term Continuing until the later of (i) the date the last patent right has lapsed, expired, or been invalidated or (ii) the expiry date of the last to expire sublicence agreement entered into pursuant to proposed licence.
DĂ©claration
RĂ©solution du Conseil de fondation
Rapport du Groupe d'experts consultatifs
Liste des pays